Payment overview · 2025
General Payments
$314.81
21 reported records · 7 companies
Healthcare provider profile · identity verified
Matthew R Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT VERNON, IN · NPI 1902842941
Verified facts
What the public records show
CMS Open Payments records show Matthew R Lee, MD received $314.81 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.08 | 51.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.13 | 13.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.75 | 11.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.74 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.23 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.52 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.81 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $138.87 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $109.05 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.13 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.21 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 147 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
70 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 653 | 136 |
| Omeprazole | Omeprazole | 506 | 133 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 416 | 107 |
| Lisinopril | Lisinopril | 381 | 98 |
| Prednisone | Prednisone | 377 | 204 |
| Furosemide | Furosemide | 375 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 101 |
| Carvedilol | Carvedilol | 355 | 85 |
| Metformin Hcl | Metformin Hcl | 337 | 86 |
| Potassium Chloride | Potassium Chloride | 333 | 87 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 330 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 319 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 79 |
| Simvastatin | Simvastatin | 279 | 74 |
| Alprazolam | Alprazolam | 268 | 50 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 266 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 254 | 56 |
| Enalapril Maleate | Enalapril Maleate | 254 | 60 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 253 | 185 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 60 |
| Azithromycin | Azithromycin | 242 | 171 |
| Gabapentin | Gabapentin | 238 | 66 |
| Losartan Potassium | Losartan Potassium | 232 | 60 |
| Meloxicam | Meloxicam | 227 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 59 |
| Allopurinol | Allopurinol | 204 | 51 |
| Atenolol | Atenolol | 186 | 42 |
| Clonidine Hcl | Clonidine Hcl | 177 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 43 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 167 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 43 |
| Eliquis | Apixaban | 147 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 139 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 37 |
| Warfarin Sodium | Warfarin Sodium | 134 | 26 |
| Ozempic | Semaglutide | 125 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 29 |
| Cephalexin | Cephalexin | 118 | 96 |
| Trazodone Hcl | Trazodone Hcl | 117 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 27 |
| Glimepiride | Glimepiride | 112 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 105 | 61 |
| Sertraline Hcl | Sertraline Hcl | 104 | 18 |
| Spironolactone | Spironolactone | 99 | 25 |
| Mupirocin | Mupirocin | 98 | 46 |
| Sucralfate | Sucralfate | 95 | 32 |
| Celecoxib | Celecoxib | 94 | 11 |
| Methylprednisolone | Methylprednisolone | 94 | 79 |
| Naproxen | Naproxen | 93 | 16 |
| Montelukast Sodium | Montelukast Sodium | 92 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 30 |
| Meclizine Hcl | Meclizine Hcl | 76 | 31 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 73 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 72 | 16 |
| Pregabalin | Pregabalin | 71 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 70 | 70 |
| Xarelto | Rivaroxaban | 70 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 68 | 14 |
| Promethazine Hcl | Promethazine Hcl | 64 | 17 |
| Fluconazole | Fluconazole | 62 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 46 |
| Farxiga | Dapagliflozin Propanediol | 55 | 11 |
| Glyburide | Glyburide | 53 | 18 |
| Nitroglycerin | Nitroglycerin | 53 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 41 |
| Famotidine | Famotidine | 47 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 14 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Glipizide | Glipizide | 39 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 35 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 13 |
| Klor-Con M20 | Potassium Chloride | 35 | 12 |
| Nystatin | Nystatin | 35 | 11 |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 16 |
| Indomethacin | Indomethacin | 31 | 21 |
| Novolog Flexpen | Insulin Aspart | 31 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 29 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 12 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 22 | 21 |
| Cilostazol | Cilostazol | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 19 |
| Lidocaine | Lidocaine | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 14 |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.81 · 21 records | ABBVIE INC. | AREXVY, ELIQUIS, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error